FDA to start releasing rejection letters shortly after issuing them

FDA to start releasing rejection letters shortly after issuing them


Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45.

The Food and Drug Administration on Thursday said it would start releasing rejection letters soon after they are provided to drugmakers, a victory for those who wanted more transparency on what has been a hidden part of the drug review process.

The agency also made public 89 so-called complete response letters (or CRLs) from 2024 and 2025 that had previously not been disclosed, including letters to Replimune, Capricor Therapeutics, and Ultragenyx, which have recently received rejections under the Trump administration. 

“This is a milestone day for the agency,” FDA Commissioner Marty Makary said in a statement. “By embracing radical transparency — one of the guiding principles of this administration — we’re giving invaluable insights to help speed therapies and cures to market, providing complete context to investors and shareholders, and above all, restoring public trust.”

STAT+ Exclusive Story

STAT+





This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *